A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277 on ClinicalTrials.gov · last registry update 2026-08-07
Recruiting now, toward 300 participants. Due to report October 2027, alongside 38 other tracked readouts that quarter. Primary outcome, as filed: Percent Change from Baseline in Body Mass Index (BMI). Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 3 June 2024 — 2 years so far. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P3
- Drug
- tirzepatideZepbound, Mounjaro
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 300
- Started
- 2024-06-03
- Primary completion
- 2027-10 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percent Change from Baseline in Body Mass Index (BMI)
Conditions studied
Obesity · Weight Gain
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.